Changchun High And New Technology Industries (Group) Inc(000661) touched the limit during the session, which was the limit for the fourth consecutive trading day.
Changchun High And New Technology Industries (Group) Inc(000661) : the impact and degree of centralized purchase on the company have not been determined
Under the fermentation of centralized purchase news, Changchun High And New Technology Industries (Group) Inc(000661) (000661) fell the limit for three consecutive trading days. On January 23, Changchun High And New Technology Industries (Group) Inc(000661) announced the abnormal fluctuation of stock trading, saying that the bidding procedure for centralized drug procurement in Guangdong Province has not been officially started, and the specific impact on the company’s performance will also depend on the actual participation of kinsay pharmaceutical in the bidding, the winning result and the winning price. The impact and degree of this centralized procurement on the company have not been determined.
Meanwhile, Changchun High And New Technology Industries (Group) Inc(000661) said that the relevant shareholders would take supplementary guarantee measures such as supplementary property mortgage, supplementary guarantee and prepayment to ensure that the mortgagee would not take the means of closing positions.
This centralized purchase has not officially started the bidding process
Looking back, on January 19, the website of Guangdong pharmaceutical trading center published relevant centralized procurement documents, which covered the growth hormone products of kinsay pharmaceutical, a subsidiary of Changchun High And New Technology Industries (Group) Inc(000661) . Affected by the news, the share price of Changchun High And New Technology Industries (Group) Inc(000661) fell by the limit on the 19th. On January 21, Changchun High And New Technology Industries (Group) Inc(000661) closed the limit again, closing at 184.36 yuan / share. So far, the limit has fallen for three consecutive days, and the total market value of the company is 74.61 billion yuan.
According to the data of the Dragon Tiger list, institutions and hot money have sold Changchun High And New Technology Industries (Group) Inc(000661) in recent three trading days. The total net sales of institutional seats exceeded 350 million yuan, and the net sales of the five business departments exceeded 530 million yuan. On January 20, there were four institutions in the top five seller seats on the Dragon Tiger list, with a total net sales of more than 170 million yuan. As of the closing on January 21, there were still 128000 selling orders at the limit price.
According to the data, the growth hormone category is divided into water injection and powder injection. Previously, insiders predicted that this round of centralized mining will include powder injection into the scope of centralized mining, and in this centralized mining notice, water injection has also been included in the scope of centralized mining. According to market analysis, in this round of centralized mining, the price reduction of water injection is much higher than that of powder injection after winning the bid. If the price structure changes significantly, Changchun High And New Technology Industries (Group) Inc(000661) will be impacted to a certain extent.
In view of the abnormal fluctuation of the company’s stock, Changchun High And New Technology Industries (Group) Inc(000661) said it had checked the relevant matters. Recently, investors have paid more attention to the documents related to centralized drug delivery procurement in Guangdong Province, Changchun High And New Technology Industries (Group) Inc(000661) introduction: on January 19, Guangdong Provincial Drug Trading Center issued the document on centralized drug delivery procurement of Guangdong alliance diclofenac and other drugs. According to the relevant documents in Schedules 1, 2 and 3 of the document, the company’s subsidiary kinsay pharmaceutical injection of recombinant human growth hormone and recombinant human growth hormone injection have been included in the scope of centralized procurement in the alliance area.
“At present, the bidding procedure for the centralized procurement of drugs has not been officially started. The specific impact on the company’s performance will also depend on the actual participation of kinsay pharmaceutical in the bidding, the winning result and the winning price. The impact and degree of this centralized procurement on the company have not been determined.” Changchun High And New Technology Industries (Group) Inc(000661) said that the company and Kinsey pharmaceutical will formulate relevant plans on the premise of not violating laws and regulations based on the practical protection of the company’s interests. In addition, the company has not found any other major events that may have a great impact on the company’s share price.
response to the pledge of shares by controlling shareholders
The pledge of Changchun High And New Technology Industries (Group) Inc(000661) controlling shareholders was also mentioned by investors. On January 20, an investor asked whether nearly 30 million shares of the shares pledged by major shareholders reached the closing line on January 20 will be closed?
In this regard, Changchun High And New Technology Industries (Group) Inc(000661) said on the interactive platform that the pledge of relevant shares of major shareholders is the pledge guarantee provided for loans from relevant banks, which is not completely consistent with the setting of the closing line of pledge type repurchase transaction. The company will remind shareholders to pay full attention to the fluctuation of stock price and avoid relevant risks.
“For the stock pledge of the controlling shareholder of the company, after confirming with the pledgor and the indirect controlling shareholder of the company, Longxiang Investment Holding Group Co., Ltd. and Changchun New Area Development Group Co., Ltd., the relevant shareholders will take supplementary guarantee measures such as supplementary property mortgage, supplementary guarantee and prepayment to ensure that the mortgagee will not take the means of closing positions.” In the announcement on January 23, Changchun High And New Technology Industries (Group) Inc(000661) responded again. Changchun High And New Technology Industries (Group) Inc(000661) also said that the state-owned assets supervision and Administration Department of Changchun new area will also pay close attention to the relevant situation to avoid risks.
It is worth mentioning that Changchun High And New Technology Industries (Group) Inc(000661) announced the increase of senior executives’ holdings and other news when the stock price fell continuously. At noon on January 21, Changchun High And New Technology Industries (Group) Inc(000661) announced that based on the good trend of the company’s development and sufficient confidence in the future development, some directors, supervisors and senior managers of the company increased their holdings of the company’s shares through centralized bidding trading in the Shenzhen Stock Exchange System on the same day. Nine Directors, supervisors and senior executives, including Ma Ji, chairman of the company, increased their holdings of 84700 shares of the company today.
At the same time, Changchun High And New Technology Industries (Group) Inc(000661) said that the time interval of the company’s actual share repurchase was from December 3, 2021 to January 21, 2022, and the company’s shares were repurchased through centralized bidding trading through the special securities account for repurchase, accounting for 0.61% of the company’s total share capital, of which the highest transaction price was 308.35 yuan / share and the lowest transaction price was 184.36 yuan / share, The total transaction amount is 600 million yuan (including transaction costs). So far, the repurchase plan of the company has been implemented.
In addition, on January 23, Changchun High And New Technology Industries (Group) Inc(000661) said that the current production and operation of the company and its branches and subsidiaries are normal, the team is stable, and the internal and external business environment has not changed significantly. The controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
